The stock will trade on pipeline catalysts rather than quarterly financials. Key binary events to watch: ZYNQUISTA NDA resubmission (Q4 2026) and SONATA-HCM topline data (Q1 2027). The $190.6M cash position funds operations through these milestones. Monitor for potential $10M milestone payment from Novo Nordisk later this year.
Drugs in focus
LXRX drug pipeline →ZYNQUISTA
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
- Time to market
- Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
- Next catalyst
- None dated
What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.
Price Chart
Executive Summary
Lexicon Pharmaceuticals reported Q2 2026 total revenue of $0.7M, a sharp decline from $28.9M in Q2 2025 which included a $27.6M licensing milestone from Novo Nordisk. Net loss widened to $31.8M ($0.07/share) vs net income of $3.3M ($0.01/share) a year ago. The quarter's focus was on pipeline execution: SONATA-HCM enrollment completed on time (topline Q1 2027), ZYNQUISTA NDA resubmission expected Q4 2026, and cash position of $190.6M provides runway through key catalysts.
Key Financial Metrics
Key Facts
- Total revenue Q2 2026: $0.7M vs $28.9M in Q2 2025 (prior year included $27.6M Novo Nordisk milestone)
- Net loss Q2 2026: $31.8M ($0.07/share) vs net income of $3.3M ($0.01/share) in Q2 2025
- SONATA-HCM Phase 3 enrollment completed, substantially exceeding 500-patient target; topline data expected Q1 2027
- ZYNQUISTA NDA resubmission for type 1 diabetes anticipated in Q4 2026
- Cash and investments: $190.6M as of June 30, 2026, up from $125.2M at Dec 31, 2025
- R&D expenses increased to $17.4M from $15.7M, driven by SONATA-HCM trial costs
- Loss on early extinguishment of debt: $4.3M in Q2 2026
Financial Impact
Revenue declined 97.6% YoY due to absence of prior-year licensing milestone; net loss of $31.8M vs prior-year net income of $3.3M; cash burn of ~$35M in H1 2026
Risk Factors
- ZYNQUISTA NDA resubmission may face delays or additional FDA data requirements
- SONATA-HCM topline results could miss efficacy endpoints
- Cash burn rate may require additional financing before reaching profitability
- INPEFA commercial revenue remains minimal at $0.7M/quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062822-26-000112 |
| Document: lxrx-20260806.htm | 0001062822-26-000112 |
| Document: 0001062822-26-000112-index-headers.html | 0001062822-26-000112 |
| Document: 0001062822-26-000112-index.html | 0001062822-26-000112 |
| Document: 0001062822-26-000112.txt | 0001062822-26-000112 |
| 8-K Data (Synthetic) | 0001062822-26-000112 |
Track record
16 reports on LXRX
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Viewing No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers